Cohort of Patients With Chronic Myelomonocytic Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data.
Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 years and over
Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
Confirmed diagnosis of chronic myelomonocytic leukemia
Regardless of stage (chronic or transformed), and whether or not currently being treated
Disqualifiers
Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
Refusal informed consent
Trial population
Cohort of Patients With Chronic Myelomonocytic Leukemia
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Sampling
Biological/VaccineBlood samples taken as part of a scheduled assessment within the context of medical care * Standard sample: 2 x 10 mL EDTA tubes * For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care * Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue sample will be considered in consultation with the surgeon (affected tissue, surrounding healthy tissue).
Treatment groups
5,000 Participants
are divided into 1 treatment groupGroup A: Cohort of patients with chronic myelomonocytic leukemia1 intervention
Trial outcomes
Primary outcomes
1
Understanding the pathophysiology of chronic myelomonocytic leukaemia
optimise diagnosis, improve prognostic stratification, identify new treatment options and assess patients' response to proposed treatments through the analysis of blood or bone marrow samples collected as part of routine care or clinical trials
Time frame
through study completion, an average of 15 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov